Literature DB >> 35838929

Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.

Gandarvakottai Senthilkumar Arumugam1, Kannan Damodharan1,2, Mukesh Doble3,4, Sathiah Thennarasu2.   

Abstract

A virus enters a living organism and recruits host metabolism to reproduce its own genome and proteins. The viral infections are intricate and cannot be completely removed through existing antiviral drugs. For example, the herpes, influenza, hepatitis and human immunodeficiency viruses are a few dreadful ones amongst them. Significant studies are needed to understand the viral entry and their growth in host cells to design effective antivirals. This review emphasizes the range of therapeutical antiviral drugs, inhibitors along with vaccines to fight against viral pathogens, especially for combating COVID-19. Moreover, we have provided the basic and in depth information about viral targets, drugs availability, their mechanisms of action, method of prevention of viral diseases and highlighted the significances of anticoagulants, convalescent plasma for COVID-19 treatment, scientific details of airborne transmission, characteristics of antiviral drug delivery using nanoparticles/carriers, nanoemulsions, nanogels, metal based nanoparticles, alike the future nanosystems through nanobubbles, nanofibers, nanodiamonds, nanotraps, nanorobots and eventually, the therapeutic applications of micro- and nanoparticulates, current status for clinical development against COVID-19 together with environmental implications of antivirals, gene therapy etc., which may be useful for repurposing and designing of novel antiviral drugs against various dreadful diseases, especially the SARS-CoV-2 and other associated variants.
© 2022. The Author(s).

Entities:  

Keywords:  Antiviral drugs; COVID-19; Drug delivery; Nanocarriers; Vaccines; Viral targets

Year:  2022        PMID: 35838929      PMCID: PMC9283561          DOI: 10.1186/s43556-022-00078-z

Source DB:  PubMed          Journal:  Mol Biomed        ISSN: 2662-8651


  173 in total

Review 1.  Nanovaccine: A novel approach in immunization.

Authors:  Seyed Mohammad Gheibi Hayat; Majid Darroudi
Journal:  J Cell Physiol       Date:  2019-01-11       Impact factor: 6.384

Review 2.  The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.

Authors:  Andrea Huwiler; Uwe Zangemeister-Wittke
Journal:  Pharmacol Ther       Date:  2017-11-08       Impact factor: 12.310

Review 3.  Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.

Authors:  Subramanian Loganathan; Sandeep N Athalye; Shashank R Joshi
Journal:  Expert Opin Biol Ther       Date:  2020-07-29       Impact factor: 4.388

Review 4.  Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems.

Authors:  Twana Mohammed M Ways; Wing Man Lau; Vitaliy V Khutoryanskiy
Journal:  Polymers (Basel)       Date:  2018-03-05       Impact factor: 4.329

Review 5.  Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Authors:  Jaffar A Al-Tawfiq; Ziad A Memish
Journal:  Expert Rev Anti Infect Ther       Date:  2016-12-24       Impact factor: 5.091

Review 6.  Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

Authors:  Jimin Xu; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  ACS Infect Dis       Date:  2020-03-10       Impact factor: 5.084

Review 7.  Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues.

Authors:  Kanika Madaan; Sandeep Kumar; Neelam Poonia; Viney Lather; Deepti Pandita
Journal:  J Pharm Bioallied Sci       Date:  2014-07

8.  Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2.

Authors:  Youngchang Kim; Robert Jedrzejczak; Natalia I Maltseva; Mateusz Wilamowski; Michael Endres; Adam Godzik; Karolina Michalska; Andrzej Joachimiak
Journal:  Protein Sci       Date:  2020-05-02       Impact factor: 6.993

9.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

10.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.

Authors:  Johanna Hansen; Alina Baum; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Elzbieta Wloga; Benjamin O Fulton; Ying Yan; Katrina Koon; Krunal Patel; Kyung Min Chung; Aynur Hermann; Erica Ullman; Jonathan Cruz; Ashique Rafique; Tammy Huang; Jeanette Fairhurst; Christen Libertiny; Marine Malbec; Wen-Yi Lee; Richard Welsh; Glen Farr; Seth Pennington; Dipali Deshpande; Jemmie Cheng; Anke Watty; Pascal Bouffard; Robert Babb; Natasha Levenkova; Calvin Chen; Bojie Zhang; Annabel Romero Hernandez; Kei Saotome; Yi Zhou; Matthew Franklin; Sumathi Sivapalasingam; David Chien Lye; Stuart Weston; James Logue; Robert Haupt; Matthew Frieman; Gang Chen; William Olson; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.